Sebastián Chiavenna
Directeur/Bestuurslid bij Inbiomotion SL
Profiel
Sebastián Chiavenna is currently the Director at Inbiomotion SL since 2022 and the Principal at Caixa Capital Risc SGEIC SA since 2020.
Previously, he worked as the Director at GlyCardial Diagnostics SL from 2021 to 2023 and as the Senior Corporate Marketing Manager at Grupo Ferrer Internacional SA from 2008 to 2020.
Mr. Chiavenna holds an undergraduate degree and a doctorate from Universidad de Buenos Aires, and an MBA from Escuela de Administración de Empresas.
Actieve functies van Sebastián Chiavenna
| Bedrijven | Functie | Begin |
|---|---|---|
Caixa Capital Risc SGEIC SA
 Caixa Capital Risc SGEIC SA Investment ManagersFinance Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital subsidiary of Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid. | Private Equity Investor | 01-01-2023 |
Inbiomotion SL
 Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Directeur/Bestuurslid | 01-04-2022 |
Eerdere bekende functies van Sebastián Chiavenna
| Bedrijven | Functie | Einde |
|---|---|---|
GlyCardial Diagnostics SL
 GlyCardial Diagnostics SL Miscellaneous Commercial ServicesCommercial Services GlyCardial Diagnostics SL has developed a biomarker called iSCOR that can detect cardiac ischemia through a blood test. The company is based in Barcelona, Spain. Early detection of ischemia can prevent myocardial damage. The Spanish company was founded in 2017 by Rafols Judit Cubedo, Lina Badimon Maestro, Capmany Teresa Padro, and Gemma Vilahur. Rafols Judit Cubedo has been the CEO since 2017. | Directeur/Bestuurslid | 01-05-2023 |
Grupo Ferrer Internacional SA
 Grupo Ferrer Internacional SA Pharmaceuticals: MajorHealth Technology Grupo Ferrer Internacional SA manufactures pharmaceutical products. It offers pharmaceuticals, consumer health and vaccines. The company was founded by Carlos Ferrer Salat in 1959 and is headquartered in Barcelona, Spain. | Corporate Officer/Principal | 01-02-2020 |
Opleiding van Sebastián Chiavenna
| Universidad de Buenos Aires | Doctorate Degree |
| Escuela de Administración de Empresas | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Caixa Capital Risc SGEIC SA
Caixa Capital Risc SGEIC SA Investment ManagersFinance Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital subsidiary of Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid. | Finance |
Grupo Ferrer Internacional SA
Grupo Ferrer Internacional SA Pharmaceuticals: MajorHealth Technology Grupo Ferrer Internacional SA manufactures pharmaceutical products. It offers pharmaceuticals, consumer health and vaccines. The company was founded by Carlos Ferrer Salat in 1959 and is headquartered in Barcelona, Spain. | Health Technology |
GlyCardial Diagnostics SL
GlyCardial Diagnostics SL Miscellaneous Commercial ServicesCommercial Services GlyCardial Diagnostics SL has developed a biomarker called iSCOR that can detect cardiac ischemia through a blood test. The company is based in Barcelona, Spain. Early detection of ischemia can prevent myocardial damage. The Spanish company was founded in 2017 by Rafols Judit Cubedo, Lina Badimon Maestro, Capmany Teresa Padro, and Gemma Vilahur. Rafols Judit Cubedo has been the CEO since 2017. | Commercial Services |
Inbiomotion SL
Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Health Technology |